• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

Trump wants a COVID vaccine before Election Day, but fewer Americans are saying they’ll get one

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
October 6, 2020, 6:00 PM ET

President Donald Trump has made it clear that he wants COVID-19 vaccine authorized before the November 3 election. That will be an uphill climb, according to pharmaceutical industry executives. Safety and efficacy standards must be met via clinical trials for a coronavirus vaccine to receive emergency use authorization (EUA), as the Food and Drug Administration stated in newly issued and long-awaited guidelines on Tuesday.

And then there’s another challenge: convincing Americans to actually get a vaccine once one receives emergency authorization. According to a new CNN poll released Monday, only 51% of those surveyed said they would try to get vaccinated if a low-cost therapy is widely available while 45% said they wouldn’t.

That’s a drop from August, when 56% said they would try to get a vaccine, and a significant falloff from May, when 66% said the same.

It’s unclear what’s driving that trend, though racial, age-related, and political demographics all seem to play a part. A far higher number of older Americans would try to get vaccinated compared to younger respondents.

The trouble with just a 51% participation rate is that it’s not high enough of a number to achieve herd immunity, wherein vaccinated people offer protection to the more vulnerable.

One solution may be education and outreach programs touted by executives as Johnson & Johnson CEO Alex Gorsky and Pfizer’s biopharmaceuticals division president Angela Hwang (both companies are working on COVID vaccines) have told recent panels held by Coins2Day.

Previous polling has also found that 60% of American voters prefer a proven and safe coronavirus vaccine than one that’s been rushed to market.

To that end, Tuesday’s new FDA guidance seems to hit that standard in defiance of Trump’s insistence at a quickly made vaccine.

Could we see a vaccine prior to the election? My take: Very unlikely.

– Trials not done yet
– FDA wants 2 months of follow-up
– Company then needs to review data and submit EUA
– FDA will then need "weeks" to review (likely 2-3)

— Alexander Gaffney (@AlecGaffney) October 6, 2020

One of the most significant elements of those guidelines—and one that would almost certainly delay a vaccine till past Election Day—is that follow-up period for trial participants before the FDA even considers an experimental treatment. But, as the previous polls show, that’s a measure most Americans find prudent.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.